PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:30 AM ET

Sponsor Check › Issuer

IT

Immunomic Therapeutics, Inc.

Corporation · organized in Delaware · formed more than five years before filing · Rockville, MD

$77.7Mreported sold (max)
60investors (max)
9offerings
13Form D filings
2012–2025filing years
0new, last 12 mo
Follow this issuerConnect me with this sponsorEmail me the full reportLook further ↓

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Jun 2, 2025 · Courts (RECAP) last checked: Oct 24, 2026, 2:12 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Immunomic Therapeutics, Inc. is a corporation organized in Delaware (formed more than five years before filing), based in Rockville, MD.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 13 Form D filings (9 originals, 4 amendments) for 9 offerings between Mar 2012 and Jun 2025. The latest filing of each offering reports a combined $104.4M sold of $140M offered to 238 investors; industry as reported: biotechnology; latest exemption Rule 506(b).

What this means A repeat filer — 9 separate raises over about 13 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: Dong-Gun Kim (executive officer and director), James Wishart (director), Ki-Hong Ahn (director), Matthew Chang (director), Robert Ahlgren (director) and 25 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

Reported money out: $3.39M in sales commissions and $530K of proceeds to officers, directors or promoters (latest filing per offering). Paid to sell it: Newport Coast Securities Inc..

What this means $530K of investor money was reported as going to the people running the deal — about 0.5% of what was sold. The form does not say what for (fees, salaries, buying something from them); ask. $3.39M went to brokers for selling it (about 3.2% of what was sold).

Activity: 0 new offerings in the last 12 months; latest amendment Jan 14, 2021; latest filing Jun 2, 2025.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Immunomic Therapeutics, Inc..

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY), property records (NYC, FL, IL and TX counties) — none found.

What this means Nothing turned up where we looked (4 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 13 public filings for Immunomic Therapeutics, Inc. and found 10 differences, 2 worth asking the sponsor about: 4 Form Ds were filed more than 15 days after the first sale; Teri Jones Heiland is no longer listed on the Jun 12, 2013 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

Business registration (state registry / Secretary of State)

State business registry (Secretary of State) 0 records matched to Immunomic Therapeutics, Inc.

No Secretary of State record matched in the registries searched (the issuer's reported state of incorporation, DE, has not been searched). Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

What the community is saying

Community search for Immunomic Therapeutics, Inc. has not run yet — it is joining a line of 34,590 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:12 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Immunomic Therapeutics, Inc...

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:12 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

10 differences found between the filings for Immunomic Therapeutics, Inc. — 2 worth asking about (compared 13 filings on Oct 24, 2026)

Note · Aug 30, 2000 – Jan 18, 2001

Bankruptcy case: Heiland v. Dovenmuehle Mortgage,Inc. — filed Aug 30, 2000

United States Bankruptcy Court, E.D. Pennsylvania docket "Heiland v. Dovenmuehle Mortgage,Inc." filed Aug 30, 2000, closed Jan 18, 2001. Teri Jones Heiland (listed on the same filings) is listed as Plaintiff ("Heiland"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗Teri Jones Heiland — PartnerFacts page ↗
Sources
Worth asking · Aug 16, 2011 – Apr 10, 2024

4 Form Ds were filed more than 15 days after the first sale

Form D filed 71 days after the first sale — Immunomic Therapeutics, Inc. · Form D filed 224 days after the first sale — Immunomic Therapeutics, Inc. · Form D filed 202 days after the first sale — Immunomic Therapeutics, Inc. · Form D filed 16 days after the first sale — Immunomic Therapeutics, Inc.

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Apr 10, 2024 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗Form D · Jun 12, 2013 ↗Form D · Mar 5, 2012 ↗
Sources
Note · Aug 16, 2011 – Jun 2, 2025

7 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Immunomic Therapeutics, Inc. (latest filing Jun 2, 2025) · No amendment in the last 12 months on an offering that may still be open — Immunomic Therapeutics, Inc. (latest filing Apr 10, 2024) · No amendment in the last 12 months on an offering that may still be open — Immunomic Therapeutics, Inc. (latest filing Mar 15, 2017) · No amendment in the last 12 months on an offering that may still be open — Immunomic Therapeutics, Inc. (latest filing Oct 15, 2014) · No amendment in the last 12 months on an offering that may still be open — Immunomic Therapeutics, Inc. (latest filing Jun 12, 2013) · and 2 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jun 2, 2025 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗Form D · Apr 10, 2024 ↗Form D · Mar 15, 2017 ↗
Sources
Worth asking · Mar 5, 2012 – Jun 12, 2013

Teri Jones Heiland is no longer listed on the Jun 12, 2013 amendment — Immunomic Therapeutics, Inc.

Teri Jones Heiland appears on the Mar 5, 2012 Form D (executive officer) but not on the Jun 12, 2013 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Mar 5, 2012 ↗Form D/A · Jun 12, 2013 ↗Teri Jones Heiland — PartnerFacts page ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jun 12, 2013 – Apr 10, 2024

5 role changes for the same people across filings

C. Eric Winzer's role changed at Immunomic Therapeutics, Inc.: executive officer, director → executive officer · William G Hearl's role changed at Immunomic Therapeutics, Inc.: executive officer, director, promoter → executive officer, director · James Wishart's role changed at Immunomic Therapeutics, Inc.: executive officer, director → director · James Wishart's role changed at Immunomic Therapeutics, Inc.: director → executive officer, director · Bernard C Rudnick's role changed at Immunomic Therapeutics, Inc.: executive officer → executive officer, director

What this means Roles on Form D are self-reported. Ask who runs the company today.

Form D/A · Jan 14, 2021 ↗Form D · Apr 10, 2024 ↗C. Eric Winzer — PartnerFacts page ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Feb 26, 2020 – Jan 14, 2021

Offering amount changed between filings — Immunomic Therapeutics, Inc.

The Feb 26, 2020 filing says $60,000,000 offered; the Jan 14, 2021 Form D/A says $77,728,230.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Feb 26, 2020 ↗Form D/A (later) · Jan 14, 2021 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Apr 24, 2014 – Oct 15, 2014

Minimum investment changed between filings — Immunomic Therapeutics, Inc.

The Apr 24, 2014 filing lists a minimum of $100,000; the Oct 15, 2014 Form D/A lists $10,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Apr 24, 2014 ↗Form D/A (later) · Oct 15, 2014 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Mar 5, 2012 – Apr 10, 2024

6 people are written more than one way across the filings

MICHAEL D. LACK is written 2 different ways on the filings · Yang Gon Jin is written 2 different ways on the filings · Ronald Thiboutot is written 2 different ways on the filings · James Wishart is written 2 different ways on the filings · Teri Jones Heiland is written 2 different ways on the filings · and 1 more

What this means Middle names and suffixes come and go on these forms. Check full legal names against your documents.

Form D · Apr 24, 2014 ↗Form D · Apr 10, 2024 ↗MICHAEL D. LACK — PartnerFacts page ↗Form D/A · Jan 14, 2021 ↗
Sources
Note · Mar 5, 2012 – Mar 15, 2017

Reported revenue range changed between filings — Immunomic Therapeutics, Inc.

"$1 - $1,000,000" (Mar 5, 2012); then "Decline to Disclose" (Mar 15, 2017).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Mar 5, 2012 ↗Form D · Mar 15, 2017 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Oct 15, 2014 – Mar 15, 2017

Address moved from Lancaster, PA to Rockville, MD — Immunomic Therapeutics, Inc.

The people listed on the Oct 15, 2014 filing give Lancaster, PA; on the Mar 15, 2017 filing they give Rockville, MD.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D/A · Oct 15, 2014 ↗Form D · Mar 15, 2017 ↗Immunomic Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

2 of 9 offerings report sales commissions totalling $3,385,129; 0 report finder's fees; 4 report proceeds to related persons totalling $530,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 2, 2025 D
File 021-547820
$0$0$0None listed on this filingEDGAR ↗
Apr 10, 2024 D
File 021-510234
$0$0$0None listed on this filingEDGAR ↗
Jan 14, 2021 D/A
File 021-361369
$3,109,129$0$0None listed on this filingEDGAR ↗
Aug 3, 2018 D
File 021-318440
$0$0$0None listed on this filingEDGAR ↗
Mar 15, 2017 D
File 021-282612
$0$0$0None listed on this filingEDGAR ↗
Oct 15, 2014 D/A
File 021-216208
$276,000$0$500,000 (est.)Newport Coast Securities Inc. BrokerCheck CRD 16944 ↗EDGAR ↗
Jun 12, 2013 D/A
File 021-174334
$0$0$10,000 (est.)None listed on this filingEDGAR ↗
Jun 12, 2013 D
File 021-197885
$0$0$10,000 (est.)None listed on this filingEDGAR ↗
Jun 12, 2013 D
File 021-197897
$0$0$10,000 (est.)None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 24, 2026, 9:30 AM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to Immunomic Therapeutics, Inc. in the sources searched.

Not found in sources searched as of Oct 24, 2026, 9:30 AM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Harris County TX (HCAD ownership rolls 2005–2026) — 1,032,426 records, loaded Oct 24, 2026, 8:00 AM ET; Dallas County TX (DCAD ownership rolls 2021–2027) — 285,535 records, loaded Oct 24, 2026, 8:20 AM ET; Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll) — 514,336 records, loaded Oct 24, 2026, 8:25 AM ET; King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published) — 538,619 records, loaded Oct 24, 2026, 8:27 AM ET; Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026) — 1,031,843 records, loaded Oct 24, 2026, 9:05 AM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Harris County TX (ownership only, no deed, mortgage or sale records; HCAD ownership rolls 2005–2026); Dallas County TX (ownership only, no deed, mortgage or sale records; DCAD ownership rolls 2021–2027); Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll); King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published); Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026); also looked up per issuer when its page is viewed. Recorder indexes (party names on deeds, mortgages and liens) in TX, AZ, NV, CA and WA counties and outside the Clerk index in FL, mortgages and liens outside NYC and Hillsborough County, lis pendens and foreclosure notices everywhere, Los Angeles County CA, Clark County NV, New York City bulk pass (not finished; per-issuer lookups only so far), Maricopa County AZ (loader ready; commercial-purpose statement not yet filed), Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 9:05 AM ET; Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 8:30 AM ET; King County WA Assessor Real Property Sales extract (EXTR_RPSale.csv) Oct 24, 2026, 8:27 AM ET; Florida DOR NAL roll (Palm Beach 60) Oct 24, 2026, 8:25 AM ET; Florida DOR NAL roll (Broward 16) Oct 24, 2026, 8:24 AM ET; Florida DOR NAL roll (Dade 23) Oct 24, 2026, 8:23 AM ET; Florida DOR NAL roll (Hillsborough 39) Oct 24, 2026, 8:21 AM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 24, 2026, 8:20 AM ET; Harris County Appraisal District real_acct.txt Oct 24, 2026, 8:00 AM ET; Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET. NYC and Cook County are also looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 9 offerings, 13 filings (one row per SEC file number)
File no.Original Form DLatest filingAmendmentsOffered (latest)Sold (latest)Industry (latest)
021-547820Jun 2, 2025 EDGAR ↗Jun 2, 2025 D EDGAR ↗0$16,000,000$6,500,000Biotechnology
021-510234Apr 10, 2024 EDGAR ↗Apr 10, 2024 D EDGAR ↗0$20,900,000$3,000,000Biotechnology
021-361369Feb 26, 2020 EDGAR ↗Jan 14, 2021 D/A EDGAR ↗1
latest Jan 14, 2021
$77,728,230$77,728,230Biotechnology
021-318440Aug 3, 2018 EDGAR ↗Aug 3, 2018 D EDGAR ↗0$314,500$314,500Biotechnology
021-282612Mar 15, 2017 EDGAR ↗Mar 15, 2017 D EDGAR ↗0$10,000,000$4,629,750Biotechnology
021-216208Apr 24, 2014 EDGAR ↗Oct 15, 2014 D/A EDGAR ↗2
latest Oct 15, 2014
$8,800,000$6,755,052Biotechnology
021-197897Jun 12, 2013 EDGAR ↗Jun 12, 2013 D EDGAR ↗0$3,000,000$2,729,500Biotechnology
021-197885Jun 12, 2013 EDGAR ↗Jun 12, 2013 D EDGAR ↗0$1,300,000$1,117,500Biotechnology
021-174334Mar 5, 2012 EDGAR ↗Jun 12, 2013 D/A EDGAR ↗1
latest Jun 12, 2013
$2,000,000$1,617,000Biotechnology

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Jun 2, 2025 D Biotechnology — $6,500,000 sold of $16,000,000 · 1 investors EDGAR ↗
FilingForm D filed Jun 2, 2025
SEC file no. 021-547820 · accession 0001543256-25-000002
Raise progress$6,500,000 sold of $16,000,000 offered (41%) · $9,500,000 remaining · first sale May 29, 2025
Filing timingDate of first sale: May 29, 2025 · Form D filed: Jun 2, 2025 (4 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale514 days (1.4 years)
Annual amendmentsIssuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byErin Duffy, Director, Finance (Jun 2, 2025)
Market contextMinimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $16,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Apr 10, 2024 D Biotechnology — $3,000,000 sold of $20,900,000 · 1 investors EDGAR ↗
FilingForm D filed Apr 10, 2024
SEC file no. 021-510234 · accession 0001543256-24-000001
Raise progress$3,000,000 sold of $20,900,000 offered (14%) · $17,900,000 remaining · first sale Jan 30, 2024
Filing timingDate of first sale: Jan 30, 2024 · Form D filed: Apr 10, 2024 (71 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale999 days (2.7 years)
Annual amendmentsIssuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byC. Eric Winzer, Chief Financial Officer (Apr 10, 2024)
Market contextMinimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $20,900,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jan 14, 2021 D/A Biotechnology — $77,728,230 sold of $77,728,230 · 6 investors EDGAR ↗
FilingForm D/A (amendment) filed Jan 14, 2021 · amends 0001543256-20-000001 ↗
SEC file no. 021-361369 · accession 0001543256-21-000001 · filing 2 of 2 in this offering
Raise progress$77,728,230 sold of $77,728,230 offered (100%) · $0 remaining · first sale Feb 18, 2020
Filing timingDate of first sale: Feb 18, 2020 · Original Form D filed: Feb 26, 2020 (8 days after first sale) · This amendment (Form D/A) filed: Jan 14, 2021
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale2,441 days (6.7 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jan 14, 2021. Most recent amendment for this offering in our index: this filing, Jan 14, 2021.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors6 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $3,109,129 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Issuer's note: The individual also received warrants to purchase 621,826 shares at $5.00 per share.
Signed byC. Eric Winzer, Chief Financial Officer (Jan 14, 2021)
Changes vs previous filing
  • total sold: $10,000,000 (Feb 26, 2020) → $77,728,230 (Jan 14, 2021)
  • total offering: $60,000,000 (Feb 26, 2020) → $77,728,230 (Jan 14, 2021)
  • remaining: $50,000,000 (Feb 26, 2020) → $0 (Jan 14, 2021)
  • investors: 1 (Feb 26, 2020) → 6 (Jan 14, 2021)
  • sales commissions: $400,000 (Feb 26, 2020) → $3,109,129 (Jan 14, 2021)
  • securities offered: Equity; Debt; Option, warrant or other right to acquire (Feb 26, 2020) → Equity; Option, warrant or other right to acquire (Jan 14, 2021)
  • may last more than one year: yes (Feb 26, 2020) → no (Jan 14, 2021)
  • related persons added (Jan 14, 2021): ALEX S KIM, YANG-GON JIN, HYUK JOO JEE, ARLO MCGINN
Compared with the D filed Feb 26, 2020 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextMinimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $77,728,230. Typical range: $2,000,000–$19,999,994.
Investors: 6. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Feb 26, 2020 D Biotechnology — $10,000,000 sold of $60,000,000 · 1 investors EDGAR ↗
FilingForm D filed Feb 26, 2020
SEC file no. 021-361369 · accession 0001543256-20-000001 · filing 1 of 2 in this offering
Raise progress$10,000,000 sold of $60,000,000 offered (17%) · $50,000,000 remaining · first sale Feb 18, 2020
Filing timingDate of first sale: Feb 18, 2020 · Form D filed: Feb 26, 2020 (8 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale2,441 days (6.7 years)
Annual amendmentsIssuer reported the offering may last more than one year. Most recent amendment for this offering in our index: Jan 14, 2021 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity; Debt; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $400,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Issuer's note: Remuneration includes warrants to purchase 80,000 shares at $5.00 per share.
Signed byC. Eric Winzer, Chief Financial Officer (Feb 26, 2020)
Market contextMinimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $60,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Aug 3, 2018 D Biotechnology — $314,500 sold of $314,500 · 1 investors EDGAR ↗
FilingForm D filed Aug 3, 2018
SEC file no. 021-318440 · accession 0001543256-18-000001
Raise progress$314,500 sold of $314,500 offered (100%) · $0 remaining · first sale Jul 18, 2018
Filing timingDate of first sale: Jul 18, 2018 · Form D filed: Aug 3, 2018 (16 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,021 days (8.3 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors1 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byC. Eric Winzer, Chief Financial Officer (Aug 3, 2018)
Market contextMinimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $314,500. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Mar 15, 2017 D Biotechnology — $4,629,750 sold of $10,000,000 · 47 investors EDGAR ↗
FilingForm D filed Mar 15, 2017
SEC file no. 021-282612 · accession 0001140361-17-012020
Raise progress$4,629,750 sold of $10,000,000 offered (46%) · $5,370,250 remaining · first sale Feb 28, 2017
Filing timingDate of first sale: Feb 28, 2017 · Form D filed: Mar 15, 2017 (15 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale3,526 days (9.7 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors47 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$25,000
Securities offeredDebt; Security to be acquired upon exercise
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byC. Eric Winzer, Chief Financial Officer (Mar 15, 2017)
Market contextMinimum investment: $25,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $10,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 47. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 15, 2014 D/A Biotechnology — $6,755,052 sold of $8,800,000 · 56 investors EDGAR ↗
FilingForm D/A (amendment) filed Oct 15, 2014 · amends 0001543256-14-000002 ↗
SEC file no. 021-216208 · accession 0001543256-14-000003 · filing 3 of 3 in this offering
Raise progress$6,755,052 sold of $8,800,000 offered (77%) · $2,044,948 remaining · first sale Dec 28, 2013
Filing timingDate of first sale: Dec 28, 2013 · Original Form D filed: Apr 24, 2014 (117 days after first sale) · This amendment (Form D/A) filed: Oct 15, 2014
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale4,684 days (12.8 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 15, 2014. Most recent amendment for this offering in our index: this filing, Oct 15, 2014.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors56 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNewport Coast Securities Inc. — FINRA BrokerCheck CRD 16944 ↗
Solicits in: CA, CT, IL, MA, MD, MN, NJ, NY, OK, PA
Money to insidersSales commissions: $276,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $500,000 (est.)
Signed byWilliam G. Hearl, CEO (Oct 15, 2014)
Changes vs previous filingNo change in the fields compared.
Compared with the D/A filed Oct 15, 2014 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $8,800,000. Typical range: $2,000,000–$19,999,994.
Investors: 56. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 15, 2014 D/A Biotechnology — $6,755,052 sold of $8,800,000 · 56 investors EDGAR ↗
FilingForm D/A (amendment) filed Oct 15, 2014 · amends 0001543256-14-000001 ↗
SEC file no. 021-216208 · accession 0001543256-14-000002 · filing 2 of 3 in this offering
Raise progress$6,755,052 sold of $8,800,000 offered (77%) · $2,044,948 remaining · first sale Dec 28, 2013
Filing timingDate of first sale: Dec 28, 2013 · Original Form D filed: Apr 24, 2014 (117 days after first sale) · This amendment (Form D/A) filed: Oct 15, 2014
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale4,684 days (12.8 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 15, 2014. Most recent amendment for this offering in our index: Oct 15, 2014 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors56 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNewport Coast Securities Inc. — FINRA BrokerCheck CRD 16944 ↗
Solicits in: CA, IL, NY, OK, PA
Money to insidersSales commissions: $276,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $500,000 (est.)
Signed byWilliam G. Hearl, CEO (Oct 14, 2014)
Changes vs previous filing
  • total sold: $1,029,000 (Apr 24, 2014) → $6,755,052 (Oct 15, 2014)
  • remaining: $7,771,000 (Apr 24, 2014) → $2,044,948 (Oct 15, 2014)
  • investors: 10 (Apr 24, 2014) → 56 (Oct 15, 2014)
  • minimum investment: $100,000 (Apr 24, 2014) → $10,000 (Oct 15, 2014)
  • sales commissions: $0 (Apr 24, 2014) → $276,000 (Oct 15, 2014)
  • proceeds to insiders: $100,000 (Apr 24, 2014) → $500,000 (Oct 15, 2014)
  • date of first sale: Apr 24, 2014 (Apr 24, 2014) → Dec 28, 2013 (Oct 15, 2014)
  • sales-compensation recipients added (Oct 15, 2014): Newport Coast Securities Inc.
Compared with the D filed Apr 24, 2014 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $8,800,000. Typical range: $2,000,000–$19,999,994.
Investors: 56. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Apr 24, 2014 D Biotechnology — $1,029,000 sold of $8,800,000 · 10 investors EDGAR ↗
FilingForm D filed Apr 24, 2014
SEC file no. 021-216208 · accession 0001543256-14-000001 · filing 1 of 3 in this offering
Raise progress$1,029,000 sold of $8,800,000 offered (12%) · $7,771,000 remaining · first sale Apr 24, 2014
Filing timingDate of first sale: Apr 24, 2014 · Form D filed: Apr 24, 2014 (0 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale4,567 days (12.5 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Oct 15, 2014 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors10 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$100,000
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $100,000 (est.)
Signed byWilliam G. Hearl, CEO (Apr 24, 2014)
Market contextMinimum investment: $100,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $8,800,000. Typical range: $2,000,000–$19,999,994.
Investors: 10. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 12, 2013 D Biotechnology — $2,729,500 sold of $3,000,000 · 36 investors EDGAR ↗
FilingForm D filed Jun 12, 2013
SEC file no. 021-197897 · accession 0001543256-13-000004
Raise progress$2,729,500 sold of $3,000,000 offered (91%) · $270,500 remaining · first sale Jun 12, 2013
Filing timingDate of first sale: Jun 12, 2013 · Form D filed: Jun 12, 2013 (0 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale4,883 days (13.4 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors36 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $10,000 (est.)
Signed byWilliam G. Hearl, CEO (Jun 12, 2013)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 12, 2013 D Biotechnology — $1,117,500 sold of $1,300,000 · 30 investors EDGAR ↗
FilingForm D filed Jun 12, 2013
SEC file no. 021-197885 · accession 0001543256-13-000003
Raise progress$1,117,500 sold of $1,300,000 offered (86%) · $182,500 remaining · first sale Oct 31, 2012
Filing timingDate of first sale: Oct 31, 2012 · Form D filed: Jun 12, 2013 (224 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,107 days (14.0 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors30 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $10,000 (est.)
Signed byWilliam G. Hearl, CEO (Jun 12, 2013)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 12, 2013 D/A Biotechnology — $1,617,000 sold of $2,000,000 · 60 investors EDGAR ↗
FilingForm D/A (amendment) filed Jun 12, 2013 · amends 0001543256-12-000001 ↗
SEC file no. 021-174334 · accession 0001543256-13-000002 · filing 2 of 2 in this offering
Raise progress$1,617,000 sold of $2,000,000 offered (81%) · $383,000 remaining · first sale Aug 16, 2011
Filing timingDate of first sale: Aug 16, 2011 · Original Form D filed: Mar 5, 2012 (202 days after first sale) · This amendment (Form D/A) filed: Jun 12, 2013
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,549 days (15.2 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jun 12, 2013. Most recent amendment for this offering in our index: this filing, Jun 12, 2013.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors60 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$50,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $10,000 (est.)
Signed byWilliam G. Hearl, CEO (Jun 12, 2013)
Changes vs previous filing
  • total sold: $1,101,260 (Mar 5, 2012) → $1,617,000 (Jun 12, 2013)
  • remaining: $898,740 (Mar 5, 2012) → $383,000 (Jun 12, 2013)
  • investors: 7 (Mar 5, 2012) → 60 (Jun 12, 2013)
  • proceeds to insiders: $0 (Mar 5, 2012) → $10,000 (Jun 12, 2013)
  • related persons no longer listed (Jun 12, 2013): Teri Heiland
Compared with the D filed Mar 5, 2012 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Mar 5, 2012 D Biotechnology — $1,101,260 sold of $2,000,000 · 7 investors EDGAR ↗
FilingForm D filed Mar 5, 2012
SEC file no. 021-174334 · accession 0001543256-12-000001 · filing 1 of 2 in this offering
Raise progress$1,101,260 sold of $2,000,000 offered (55%) · $898,740 remaining · first sale Aug 16, 2011
Filing timingDate of first sale: Aug 16, 2011 · Form D filed: Mar 5, 2012 (202 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,549 days (15.2 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 12, 2013 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors7 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$50,000
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byWilliam G. Hearl, CEO (Mar 5, 2012)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Amendment history — 4 amendments on this page, each compared with the filing before it in the same offering
Amendment filedFile no.Compared withWhat changed (both values as filed)
Jan 14, 2021 EDGAR ↗021-361369Feb 26, 2020 Dtotal sold: $10,000,000 (Feb 26, 2020) → $77,728,230 (Jan 14, 2021) · total offering: $60,000,000 (Feb 26, 2020) → $77,728,230 (Jan 14, 2021) · remaining: $50,000,000 (Feb 26, 2020) → $0 (Jan 14, 2021) · and 5 more (open the filing above)
Oct 15, 2014 EDGAR ↗021-216208Oct 15, 2014 D/ANo change in the fields compared
Oct 15, 2014 EDGAR ↗021-216208Apr 24, 2014 Dtotal sold: $1,029,000 (Apr 24, 2014) → $6,755,052 (Oct 15, 2014) · remaining: $7,771,000 (Apr 24, 2014) → $2,044,948 (Oct 15, 2014) · investors: 10 (Apr 24, 2014) → 56 (Oct 15, 2014) · and 5 more (open the filing above)
Jun 12, 2013 EDGAR ↗021-174334Mar 5, 2012 Dtotal sold: $1,101,260 (Mar 5, 2012) → $1,617,000 (Jun 12, 2013) · remaining: $898,740 (Mar 5, 2012) → $383,000 (Jun 12, 2013) · investors: 7 (Mar 5, 2012) → 60 (Jun 12, 2013) · and 2 more (open the filing above)

Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Jun 2, 2025. Industry as reported, by offering: All 9 offerings reported: Biotechnology (2012–2025).

Key people 20

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

NameRelationshipAddress stateOn filings (first → last)Also listed on
DK Dong-Gun KimExecutive Officer, DirectorMDApr 10, 2024 → Jun 2, 2025
on 2 of 13 filings
listed on the latest filing
1 other issuer
JW James Wishart
also filed as James W. Wishart
Director, Executive Officer
Issuer's note: Secretary and Director
MDMar 5, 2012 → Jun 2, 2025
on 13 of 13 filings
listed on the latest filing
2 other issuers
KA Ki-Hong AhnDirectorMDApr 10, 2024 → Jun 2, 2025
on 2 of 13 filings
listed on the latest filing
—
MC Matthew ChangDirectorMDApr 10, 2024 → Jun 2, 2025
on 2 of 13 filings
listed on the latest filing
—
RA Robert AhlgrenDirectorMDApr 10, 2024 → Jun 2, 2025
on 2 of 13 filings
listed on the latest filing
—
SP Steve ParkDirectorMDApr 10, 2024 → Jun 2, 2025
on 2 of 13 filings
listed on the latest filing
—
YJ Yang Gon Jin
also filed as Yang-gon JIN
DirectorMDJan 14, 2021 → Jun 2, 2025
on 3 of 13 filings
listed on the latest filing
1 other issuer
CW C. Eric WinzerExecutive Officer, Director
Issuer's note: Chief Financial Officer and Director
MDMar 15, 2017 → Apr 10, 2024
on 5 of 13 filings
not listed on the latest filing (Jun 2, 2025)
3 other issuers
ML Michael Lack
also filed as Michael D. Lack
DirectorPAApr 24, 2014 → Apr 10, 2024
on 8 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
RT Ronald Thiboutot
also filed as Ronald P. Thiboutot
DirectorPAMar 5, 2012 → Apr 10, 2024
on 12 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
AK Alex S KIMDirectorMDJan 14, 2021
on 1 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
AM Arlo McginnDirectorMDJan 14, 2021
on 1 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
HJ Hyuk JOO JEEDirectorMDJan 14, 2021
on 1 of 13 filings
not listed on the latest filing (Jun 2, 2025)
1 other issuer
WH William G. Hearl
also filed as William G Hearl
Executive Officer, Director, Promoter
Issuer's note: Chief Executive Officer and Director
PAMar 5, 2012 → Jan 14, 2021
on 11 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
WM William Barry Mcdonald
also filed as William Barry McDonald
DirectorMDMar 5, 2012 → Aug 3, 2018
on 9 of 13 filings
not listed on the latest filing (Jun 2, 2025)
1 other issuer
BR Bernard C. Rudnick
also filed as Bernard C Rudnick
Executive Officer, Director
Issuer's note: Chief Financial Officer and Director
PAMar 5, 2012 → Oct 15, 2014
on 7 of 13 filings
not listed on the latest filing (Jun 2, 2025)
1 other issuer
BM Bruce F. Mackler
also filed as Bruce Mackler · person page: Bruce F Mackler
Executive Officer, Director
Issuer's note: Vice President for Regulatory Affairs and Director
MDMar 5, 2012 → Oct 15, 2014
on 7 of 13 filings
not listed on the latest filing (Jun 2, 2025)
4 other issuers
TH Teri Jones Heiland
also filed as Teri Heiland
Executive Officer
Issuer's note: Vice President--Research and Development
PAMar 5, 2012 → Oct 15, 2014
on 4 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
LS Lisa SalleyExecutive Officer
Issuer's note: Chief Operating Officer
PAMar 5, 2012 → Jun 12, 2013
on 4 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—
WL Winston I LoweExecutive Officer
Issuer's note: General Counsel and Secretary of the Board of Directors
PAMar 5, 2012 → Jun 12, 2013
on 4 of 13 filings
not listed on the latest filing (Jun 2, 2025)
—

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (James I Wishart; James D. Wishart; James ERIC Wishart; Ki-Hong ERIC Ahn; Matthew ERIC Chang; Robert ERIC Ahlgren; Steve ERIC Park; YANG-GON P. JIN; Yang Gon ERIC Jin; Michael ERIC Lack; Ronald I Thiboutot; Ronald D. Thiboutot; Ronald ERIC Thiboutot; ARLO P. MCGINN; HYUK JOO P. JEE; Bruce C Mackler; Teri Barry Heiland; Lisa C Salley) — the filing on EDGAR is the source.

Connections

Other issuers listing the same people:

Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Immunomic Therapeutics, Inc..

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for Immunomic Therapeutics, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in Immunomic Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #69,044 of 374,652 in line (1,386 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for MD yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for Immunomic Therapeutics, Inc., plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Rockville, MD). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn companies ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Maryland Judiciary case search ↗Delaware CourtConnect ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Maryland Secretary of State business search ↗Delaware Secretary of State business search ↗OpenCorporates ↗